Clinical Trial Search

Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants

Primary: Change From Baseline in Self-Reported Symptom Scores From Well-to-Sick State Through Day 56 — 0.065; 0.281; 0.036; 0.113 Scores on a scale — p=<.0001

Primary: Number of Subjects That Are Alive Without Respiratory Failure at Day 29. — 17; 14 Participants

Primary: Change of Arterial Oxygenation at 48 Hours From Enrollment — 200; 183 ratio

Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year

Primary: Time to Hospital Discharge — 7.1; 7.5 Days — p=0.5634

Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant

Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg

Primary: Number of Participants Having Adverse Events — 1; 2; 2; 4 Participants

Primary: Mechanical Ventilation — 1; 1 Participants

Primary: Number of Participants Who Survived and Died — 1; 31; 14; 19 Participants

Primary: Improvement in Oxygenation — 25.7; 29.7 ratio

Primary: Change in Oxygenation Index (OI) — -0.7; -1.5; 0.8; -1.1 cmH20/mmHg — p=0.34

Primary: Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol — 10; 10 Participants

Primary: Incidence of Pre-specified Infusion Associated Adverse Events — 0; 0; 0 participants

Primary: Percentage of Sputum Samples Positive for Bacterial Pathogens as Identified by Bacteriological Methods, in Any Stable COPD Patients and During AECOPDs — 74.2; 78; 94.6…

Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants

Primary: Acute Chest Syndrome — 11; 11; 22; 85 participants

Primary: Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion — 0; 0 Participants

Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants

Primary: Number of Participants Receiving Mechanical Ventilation — 51; NA participants

Primary: Subjects Alive and Off of Oxygen at Day 14 — 12; 9 Participants

Primary: Proportion of Subjects Alive and Off Oxygen at 14 Days — 1; 0 Participants

Primary: Proportion of Subjects Alive and Off of Oxygen at Day 14 — 1; 1 Participants

Primary: Subjects Discharged From the Hospital Alive and Without the Need for Mechanical Ventilation. — 10; 10 Participants

Primary: Number of Patients With Any TEAEs During the Treatment Period Baseline to Day 14 — 5; 10 Participants

Primary: Change in Exhaled Breath Metabolites — 3298 breath metabolites

Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by Protocol Definition of AE — 3; 0; 0; 1 Participants

Primary: Percentage of Participants Alive and Without Respiratory Failure Through Day 28 — 86.4; 79.2 percentage of participants — p==0.599

Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants